Abstract
BackgroundDepression is one of the most predominant mental health issues that are prevalent now. Therefore, many clinical trials were being conducted to find the safest, most effective, and tolerable anti-depressant. This study aims to compare desvenlafaxine and sertraline regarding their safety and efficacy in treating depression.MethodologyThe patients who were diagnosed with depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria were included in the study and were divided into two groups. The severity of depression in these patients was evaluated using Beck Depression Inventory and Hamilton depression scale (HAM-D) before and after the treatment (four weeks).ResultsAbout 64% of the study sample were males, and 36% were females, with 77% of the patients in the desvenlafaxine group taking 100 mg dosage and about 74% patients taking 50 mg dosage in the sertraline group. The patients in both groups showed statistically significant (p < 0.00001) improvement after using these drugs.ConclusionBoth desvenlafaxine and sertraline showed their efficacy in treating depression by improving the clinical outcome in patients. Sertraline was marginally better in clinical results. Finally, it is advisable to carry out more randomized trials to improve the patient’s quality of life.
Highlights
This study aims to compare desvenlafaxine and sertraline regarding their safety and efficacy in treating depression
The main aim of this study is to find out a better drug profile between sertraline and desvenlafaxine in relation to their safety, efficacy, and tolerability by patients suffering from a major depressive disorder
Selection bias of the study subjects could be avoided by randomization, which we recommend for future studies. Both sertraline and desvenlafaxine showed efficacy in treating depression and were well-tolerated as indicated by the application of the Hamilton depression scale (HAM-D) and Beck Depression Inventory, meeting the hypothesis given by the author
Summary
In a person's lifetime, the estimated occurrence of at least one episode of major depressive disorder is about 17% [1]. This occurrence causes psychiatrists and physicians to encounter this disorder often in their clinics. Patients suffering from depression experience difficulties in their social functioning and have impaired work output [2-3]. All this has led to the recognition of depression as the fourth most leading disability globally [4]. Depression is most commonly treated in three divided stages - acute, continuation, and maintenance phases [10]. This study aims to compare desvenlafaxine and sertraline regarding their safety and efficacy in treating depression
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
